Largest vaccine manufacturing plant in South America to be commissioned in March 2019
A new vaccine manufacturing plant, which was opened in Nicaragua two years ago, should start its official operations from March 2019 after receiving all the needed certifications for the facility, according to recent statements by the director of the St Petersburg Research Institute of Vaccines and Serums of Russia (SPbNIIVS) Viktor Trukhin, the person who oversees implementation of the project.
Mr Trukhin said a significant delay in the launch of the plant was mainly due to serious disruptions with the supplies of the needed equipment that were committed by some of the contractors from India, reports The Pharma Letter’s local correspondent.
The decision to build the plant was taken by the intergovernmental commission of Russia and Nicaragua in 2013.Technical commissioning of the plant took place on October 22, 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze